Source: Annual Congress 2006 - Recent advances in the treatment of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. A. Molfino, S. Mallikaarjun, P. Zhang, S. Shoaf, K. Mitsui (Rockville, United States Of America). Efficacy and tolerability of tetomilast, a new inhibitor of neutrophilic inflammation, in chronic obstructive pulmonary disease. Eur Respir J 2006; 28: Suppl. 50, 3048

Member's Comments

No comment yet.

Related content which might interest you: Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Fenspiride efficacy in the treatment of chronic obstructive pulmonary disease Source: International Congress 2017 – Novel mechanisms and treatments for COPD Year: 2017 Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Inferon efficacy in the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Source: Eur Respir J 2003; 21: 912 Year: 2003 Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Safety and effectiveness of sputum induction in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 67s Year: 2001 Modulation of airway inflammation to prevent exacerbations of COPD Source: Eur Respir Rev 2005; 14: 78-82 Year: 2005 Cilomilast is efficacious in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 68s Year: 2003 A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002 Beyond corticosteroids: future prospects in the management of inflammation in COPD Source: Eur Respir Rev 2011; 20: 175-182 Year: 2011 Comparison of the efficacy of azythromycin and roxithromycin in the treatment of acute purulent exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 138s Year: 2001 The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005 Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005 Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001 Mucoactive therapy in COPD Source: Eur Respir Rev 2009; 19: 134-140 Year: 2010 Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001 Systemic effects of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 347-360 Year: 2003